These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 20617420)

  • 1. Prasugrel: a novel platelet ADP P2Y(12) receptor antagonist.
    Mousa SA; Jeske WP; Fareed J
    Methods Mol Biol; 2010; 663():221-8. PubMed ID: 20617420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
    Mousa SA; Jeske WP; Fareed J
    Clin Appl Thromb Hemost; 2010 Apr; 16(2):170-6. PubMed ID: 20299391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical profile of prasugrel, a novel thienopyridine.
    Angiolillo DJ; Bates ER; Bass TA
    Am Heart J; 2008 Aug; 156(2 Suppl):S16-22. PubMed ID: 18657682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention.
    Capranzano P; Ferreiro JL; Angiolillo DJ
    Expert Rev Cardiovasc Ther; 2009 Apr; 7(4):361-9. PubMed ID: 19379060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prasugrel: a novel platelet ADP P2Y12 receptor antagonist. A review on its mechanism of action and clinical development.
    Angiolillo DJ; Suryadevara S; Capranzano P; Bass TA
    Expert Opin Pharmacother; 2008 Nov; 9(16):2893-900. PubMed ID: 18937620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile.
    Jakubowski JA; Winters KJ; Naganuma H; Wallentin L
    Cardiovasc Drug Rev; 2007; 25(4):357-74. PubMed ID: 18078435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients.
    Tcheng JE; Mackay SM
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):83-91. PubMed ID: 22316323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing platelet P2Y12 inhibition for patients undergoing PCI.
    Steinhubl S; Roe MT
    Cardiovasc Drug Rev; 2007; 25(2):188-203. PubMed ID: 17614940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prasugrel: a novel platelet ADP P2Y receptor antagonist.
    Wilson W; Gurvitch R; Ajani AE
    Cardiovasc Ther; 2009; 27(3):194-8. PubMed ID: 19689619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
    Toth PP
    Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial.
    Wiviott SD; Antman EM; Winters KJ; Weerakkody G; Murphy SA; Behounek BD; Carney RJ; Lazzam C; McKay RG; McCabe CH; Braunwald E;
    Circulation; 2005 Jun; 111(25):3366-73. PubMed ID: 15967851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study.
    Trenk D; Stone GW; Gawaz M; Kastrati A; Angiolillo DJ; Müller U; Richardt G; Jakubowski JA; Neumann FJ
    J Am Coll Cardiol; 2012 Jun; 59(24):2159-64. PubMed ID: 22520250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P2Y12 inhibitors in cardiovascular disease: focus on prasugrel.
    Scott DM; Norwood RM; Parra D
    Ann Pharmacother; 2009 Jan; 43(1):64-76. PubMed ID: 19050170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis.
    van Giezen JJ; Berntsson P; Zachrisson H; Björkman JA
    Thromb Res; 2009 Nov; 124(5):565-71. PubMed ID: 19692114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
    Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J
    Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic basis of the antiplatelet action of prasugrel.
    Schrör K; Siller-Matula JM; Huber K
    Fundam Clin Pharmacol; 2012 Feb; 26(1):39-46. PubMed ID: 21895761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel antiplatelet strategies in acute coronary syndromes.
    Sabatine MS
    Cleve Clin J Med; 2009 Apr; 76 Suppl 1():S8-15. PubMed ID: 19332592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes.
    Baker WL; White CM
    Am J Cardiovasc Drugs; 2009; 9(4):213-29. PubMed ID: 19655817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thienopyridines and other ADP-receptor antagonists.
    Bernlochner I; Sibbing D
    Handb Exp Pharmacol; 2012; (210):165-98. PubMed ID: 22918731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prasugrel for arterial coronary thrombosis.
    Serebruany V; Makarov L
    Drugs Today (Barc); 2009 Feb; 45(2):83-91. PubMed ID: 19343228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.